Genus Settles Lawsuit with ASM on Favorable Terms

Sunnyvale, Calif.-April 11th, 2003-Genus, Inc. (Nasdaq: GGNS) announced today that it has settled its lawsuit with ASM International (Nasdaq: ASMI) et al ("ASM") on favorable terms. This settlement follows the judgments of non-infringement Genus obtained regarding U.S. Patent Nos. 6,015,590 and 5,916,365, which relate to atomic layer deposition ("the ALD patents").

Under the terms of the agreement, Genus has gained a royalty-free license for all conduct past, present and future to each of the patents ASM asserted in the litigation, including both ALD patents as well as ASM's U.S. Patent No. 4,798,165. By specific agreement of the parties, these licenses are applicable to Genus' successors and affiliates. Genus has likewise obtained a covenant from ASM that it will not sue Genus for patent infringement or antitrust violations for the next five years.

In return, Genus has granted ASM and its successors and affiliates a royalty-free license to the patent Genus asserted in the litigation, U.S. Patent No. 5,294,568, and has agreed to dismiss its antitrust claims against ASM. Genus has also agreed not to sue ASM for patent infringement or antitrust violations for the next five years.

No payments have been made by either Genus or ASM in exchange for these licenses and the covenant not to sue. However, under the terms of the agreement, ASM has the right to pursue an appeal of the District Court's judgments of non-infringement regarding the ALD patents. The agreement specifies that if the Federal Circuit vacates either of the existing judgments related to the ALD patents based on a change in the District Court's claim construction, Genus will pay ASM $1 million for the royalty-free licenses to the ALD patents it has been granted under the agreement. Otherwise, Genus will pay nothing for these licenses.

Bill Elder, Genus's CEO, commented, "I am pleased that we were able to reach this resolution of our dispute with ASM. The agreement gives Genus royalty-free licenses to what ASM's Chief Executive Officer has described as its 'pioneering ALD patents,' and validates our previous statements about the strength of our litigation position."

About ASM
ASM International N.V. is headquartered in Bilthoven, the Netherlands. ASM International is a global company, serving one of the most important and demanding industries in the world. The Company possesses a strong technological base, state-of-the-art manufacturing facilities, a competent and qualified workforce and a highly trained, strategically distributed support network. ASM International's subsidiaries design and manufacture equipment and materials used to produce semiconductor devices. ASM International and its subsidiaries provide production solutions for wafer processing, assembly and packaging through their facilities in the United States, Europe, Japan and Asia. ASM International's common stock shares trade on Nasdaq (symbol ASMI) and the Euronext Stock Exchange in Amsterdam (symbol ASM). For more information, visit ASM's web site at http://www.asm.com

About Genus
Genus, Inc. manufactures critical deposition processing products for the global semiconductor industry and the data storage industry. To enable the production of intricate micro-computer chips and electronic storage devices, Genus offers its LYNX and StrataGem series production-proven equipment for 200mm and 300mm semiconductor production, and offers thin film deposition products for chemical vapor deposition (CVD), atomic layer deposition (ALD), and pre-clean capabilities. Genus is at the forefront of market and technology developments in the ALD marketplace, which is gaining acceptance worldwide as a critical technology for sub 0.13-micron production of computer chips and electronic storage devices. Genus' customers include semiconductor manufacturers located throughout the United States, Europe and the Pacific Rim including Korea, Japan and Taiwan. Founded in 1981, the company is headquartered in Sunnyvale, California. For additional information visit Genus' web site at www.genus.com

NOTE: LYNX2®, LYNX3™ and StrataGem™ are trademarks of Genus, Inc

Forward-Looking Statements
This press release contains forward-looking statements regarding the company's future financial and business performance. These forward-looking statements are subject to a number of risks and uncertainties. These contingencies include but are not limited to: actual customer orders received by the company, the extent to which ALD technology is demanded by the marketplace, the actual number of customer orders received by the company, availability of components from suppliers, the timing of final acceptance of products by customers, the financial climate, accessibility to financing and fulfillment of closing conditions, general conditions in the thin film equipment market and in the macro-economy, and the influence of global political events. Genus assumes no obligation to update this information. Additional risks and uncertainties are discussed in the Management's Discussion and Analysis of Results of Operations contained in Genus' Annual Report on Form 10-K for the fiscal year ended December 31, 2001 and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission.